Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

      09:35 - 09:40  |  Presenter: Qing Zhou

      • Abstract

      Loading...

  • +

    MA03 - Biomarkers for Immunotherapy: Are All Relevant?

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors

      11:20 - 11:25  |  Presenter: Wei Nie

      • Abstract

      Loading...

  • +

    FP04 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

      00:00 - 00:00  |  Presenter: Jie Wang

      • Abstract

      Loading...

  • +

    P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the Treatment Journey in NSCLC with Immuno-oncology and EGFR-TKIs

    • 05:15 - 06:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS04.03 - Translating the Clinical Benefits of EGFR-TKIs across EGFRm NSCLC

      05:35 - 05:50  |  Presenter: Zhijie Wang

      • Abstract

      No abstract available for this presentation

  • +

    WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer

    • 22:15 - 23:45
    • 9/11/2021
    • Location: Program Auditorium
    • Not for CME Credit
    • Type: Workshop
    • Track: N.A.
    • +

      WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

      22:53 - 23:03  |  Presenter: Jie Wang

      • Abstract

      Loading...

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

      19:05 - 19:15  |  Presenter: Alexander Spira

      • Abstract

      Loading...

  • +

    MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

      18:05 - 18:10  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

      18:10 - 18:15  |  Presenter: Jie Wang

      • Abstract

      Loading...